About ICU Medical, Inc.
https://www.icumed.comICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide.
CEO
Vivek Jain
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2002-03-18 | Forward | 3:2 |
| 1993-04-01 | Forward | 3:2 |
ETFs Holding This Stock
XSMH.TO
Weight:0.24%
Shares:1.46M
IJR.AX
Weight:0.24%
Shares:1.46M
VTS.AX
Weight:0.01%
Shares:736.42K
Summary
Showing Top 3 of 169
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:3.52M
Value:$523.03M
BLACKROCK INC.
Shares:3.25M
Value:$482.84M
VANGUARD GROUP INC
Shares:2.62M
Value:$389.86M
Summary
Showing Top 3 of 383
About ICU Medical, Inc.
https://www.icumed.comICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $536.99M ▼ | $187.16M ▼ | $-3.4M ▼ | -0.63% ▼ | $-0.14 ▼ | $66.56M ▼ |
| Q2-2025 | $548.87M ▼ | $197.48M ▲ | $35.34M ▲ | 6.44% ▲ | $1.43 ▲ | $106.41M ▲ |
| Q1-2025 | $604.7M ▼ | $197.22M ▲ | $-15.48M ▲ | -2.56% ▲ | $-0.63 ▲ | $63.8M ▼ |
| Q4-2024 | $629.8M ▲ | $189.57M ▼ | $-23.83M ▲ | -3.78% ▲ | $-0.97 ▲ | $87.42M ▲ |
| Q3-2024 | $589.13M | $196.62M | $-32.98M | -5.6% | $-1.35 | $64.96M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $299.73M ▼ | $4.1B ▼ | $1.98B ▼ | $2.13B ▲ |
| Q2-2025 | $300.02M ▲ | $4.11B ▼ | $1.99B ▼ | $2.12B ▲ |
| Q1-2025 | $289.7M ▼ | $4.18B ▼ | $2.2B ▼ | $1.99B ▲ |
| Q4-2024 | $308.57M ▼ | $4.2B ▼ | $2.24B ▼ | $1.97B ▼ |
| Q3-2024 | $312.51M | $4.31B | $2.26B | $2.05B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.4M ▼ | $56.71M ▲ | $-30.03M ▼ | $-25.69M ▲ | $-293K ▼ | $27.63M ▲ |
| Q2-2025 | $35.34M ▲ | $11.21M ▼ | $187.46M ▲ | $-195.01M ▼ | $10.32M ▲ | $-10.79M ▼ |
| Q1-2025 | $-15.48M ▲ | $51.33M ▲ | $-16.81M ▲ | $-56.34M ▼ | $-18.86M ▼ | $36.71M ▲ |
| Q4-2024 | $-23.83M ▲ | $40.19M ▲ | $-26.55M ▼ | $-8.19M ▲ | $-3.95M ▼ | $13.6M ▼ |
| Q3-2024 | $-32.98M | $36.1M | $-22.86M | $-10.38M | $9.86M | $21.55M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Equipment revenue | $0 ▲ | $0 ▲ | $30.00M ▲ | $50.00M ▲ |
 Government Grant Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Infusion Consumables | $270.00M ▲ | $270.00M ▲ | $0 ▼ | $0 ▲ |
 Infusion Systems | $170.00M ▲ | $170.00M ▲ | $0 ▼ | $0 ▲ |
 Other deferred revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Software revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Vital Care | $190.00M ▲ | $170.00M ▼ | $0 ▼ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Asia Pacific | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ |
 EMEA | $100.00M ▲ | $120.00M ▲ | $100.00M ▼ | $100.00M ▲ |
 Other Foreign Countries | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ |
 UNITED STATES | $410.00M ▲ | $310.00M ▼ | $390.00M ▲ | $340.00M ▼ |
CEO
Vivek Jain
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2002-03-18 | Forward | 3:2 |
| 1993-04-01 | Forward | 3:2 |
ETFs Holding This Stock
XSMH.TO
Weight:0.24%
Shares:1.46M
IJR.AX
Weight:0.24%
Shares:1.46M
VTS.AX
Weight:0.01%
Shares:736.42K
Summary
Showing Top 3 of 169
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:3.52M
Value:$523.03M
BLACKROCK INC.
Shares:3.25M
Value:$482.84M
VANGUARD GROUP INC
Shares:2.62M
Value:$389.86M
Summary
Showing Top 3 of 383